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Original Article
Outbreak of Dengue Fever in Karachi 2006: a clinical perspective
Muhammad Mehmood Riaz,1 Khalid Mumtaz,2 Muhammad Shoaib Khan,3 Junaid Patel,4
Muhammad Tariq,5 Harith Hilal,6 Shaheryar Ahmed Siddiqui,7 Farrukh Shezad8
Department of Medicine,1,2,4,5 MBBS, Research Assistant,3,6-8 Aga Khan University Hospital, Karachi, Pakistan.
Abstract
Objective: This study reports clinical manifestations and spectrum of severity of dengue fever (DF), dengue
haemorrhagic fever (DHF) and dengue shock syndrome (DSS) in adult patients admitted during 2006 outbreak
in Karachi. A rough estimation of cost of care was also calculated.
Methods: A cross-sectional study was done at a tertiary care hospital in Karachi from January to December
2006. Patients suspected of having DF with positive dengue IgM antibodies were included and records were
reviewed. Patients were divided into DF, DHF and DSS as per WHO classification, and the severity of clinical
manifestations was determined.
Results: A total of 278(65.72%) of 423 patients admitted with suspected dengue illness had positive IgM titer.
Mean age was 31±12.9 years, with 168(60%) males and 110(40%) females. Common presenting symptoms
were fever (100%), vomiting (78%), epigastric pain (52%), bleeding tendencies (34%), and erythematous rash
(33%). Thrombocytopenia (60%), Leucopenia (45%), elevated transaminases (ALT 71%; AST 88%), and
deranged PT (22%) and  aPTT (75%) were the predominant.
Laboratory parameters: DF was diagnosed in  169(61%) patients, 82 (29%) were classified as DHF, and
27(10%) as DSS. Patients with DHF/DSS were younger <30 years (n=60, 55%) and had longer hospital stay
(p=0.001). Case fatality rate for DHF/DSS group was 4.6%.
Conclusion: It was estimated that endemicity of DF is on the rise in Karachi and a significant proportion of patients
had DHF and DSS. Younger patients develop DHF and DSS and have high case fatality rate (JPMA 59:339; 2009).
Introduction
Over the last few years dengue has become a major
international health problem affecting tropical and subtropical
regions around the world, especially in urban and peri-urban
areas. It is the most common arbovirosis in the world and also
the most important one in terms of morbidity and mortality.1
The World Health Organization (WHO) estimates that more
than 2.5 billion people are at risk of dengue infection.2
Dengue fever is an acute infectious disease caused by
an arbovirus in the Flavivirus genus. The disease
manifestations range from a flu like illness known as dengue
fever (DF) to a severe and at times fatal disease characterized
by haemorrhage and/or shock, known as dengue haemorrhagic
fever/dengue shock syndrome (DHF/DSS). There are four viral
serotypes (DEN-1, DEN-2, DEN-3, and DEN-4). The virus
transmits from viraemic to susceptible humans mainly by bites
of the Aedes aegypti and Aedes albopictus mosquito species.3
In Southeast Asia, DF is a disease of childhood. There is,
however, evidence to suggest that the incidence of DHF among
adults is inceasing.4 DHF is a life threatening complication of
dengue infection manifested by high fever of 2-7 days,
haemorrhagic phenomena, and thrombocytopenia. Some
patients may progress to shock known as DSS. If the illness is
not identified early in the course and not treated promptly when
indicated, case fatality rates (CFRs) of DHF can go over 20 per
cent and that of DSS can be as high as 44 %.5 Severe illness
among adults with higher CFRs has already been reported from
India and Bangladesh.6
In Pakistan the first out break of DF was observed in
1994.7 In the subsequent years sporadic cases of suspected
dengue infection were reported. During the last few months of
2005, we began to see more than usual number of patients with
undifferentiated fever and thrombocytopenia. Many patients
were found to be positive for dengue IgM. Few had
unexplained encephalitis, fulminant hepatic failure,
disseminated intravascular coagulation and haemorrhage. This
study was undertaken to determine the severity of clinical
manifestations of DF and DHF/DSS in adult patients. We also
studied the predictive markers for severity of the disease and
estimated the average cost of management of different subsets
of patients in a tertiary care referral centre.
Patients and Methods
This cross-sectional study was undertaken in the
Medical unit of Aga Khan University Hospital (AKUH)
Karachi, Pakistan from January 1st to December 31st, 2006. A
total of 423 patients were hospitalized with suspicion of
dengue infection. 
Two hundred and seventy eight patients, who had acute
febrile illness, a positive test for dengue IgM antibodies by
standard serological test of ELISA technique and with two or
more of the following manifestations: headache, retro-orbital
pain, myalgia, arthralgia, rash, leucopenia, and haemorrhagic
manifestations were incorporated as cases of dengue. Informed
consent was taken from all the patients or their relatives (next
of kin) before enrolling them into the study. Clinical,
haematological and biochemical findings were recorded
serially until discharge. Sera from all suspected cases were
tested for dengue IgM antibodies after 5-6 days of fever in the
main laboratory of the hospital. Enteric fever was ruled out by
performing blood cultures where indicated. Malaria and sepsis
were excluded by peripheral thick and thin film examination
and/or immuno-chromatographic antigen detection for malaria
(ICT) and blood cultures for sepsis respectively. The WHO
classification and case definitions were used to classify the
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Table-1: WHO criteria for diagnosis of Dengue fever, Dengue
hemorrhagic fever, Dengue Shock Syndrome.
Probable Dengue Fever (DF)
Acute febrile illness with 2 or more of the following manifestations:
1. Headache 2. Retro-orbital pain
3. Myalgia 4. Arthralgia
5. Rash 6. Haemorrhagic manifestations
7. Leucopenia; and Supportive serology; or
Occurrence at the same location and time as other confirmed cases
of dengue
Confirmed DF
Case confirmed by laboratory criteria (isolation of the dengue virus, 4-fold
or greater change in antibody titers, demonstration of the dengue virus
antigen or genomic sequence).
Dengue Haemorrhagic Shock (DHF)
All of following must be present
1.  Confirmed dengue fever through laboratory
2.  Fever for 2-7 days
3.  Bleeding evidenced by at least one of the following:
a. Positive tourniquet test (TT),
b. Petechiae, ecchymosis, or purpura,
c. Bleeding from the mucosa, gastrointestinal tract, injection sites
or others.
d. Haematemesis or malaena
e. Thrombocytopenia (100,000 /mm3 or less),
f.  Evidence of plasma leakage due to increased vascular    
4.  Permeability, manifested by at least one of the following:
a. Rise in the haematocrit > 20% above average for age, sex,
population.
b. Drop in the haematocrit following volume-replacement
treatment > 20% 
c. Signs of plasma leakage e.g., pleural effusion, ascites,
hypoproteinaemia
Dengue Shock Syndrome (DSS)
1. Four criteria of DHF 
2. Plus signs of circulatory failure manifested as 
a. Rapid and weak pulse
b. Narrow pulse pressure (<20mmHg)
c. Hypotension for age (Sys Press<80mmHg for <5yrs,
<90mmHg for>5yrs)
d. Cold, clammy skin
e. Restlessness
disease as DF, DHF and DSS.8 Refer to Table 1.
A chest radiograph was obtained in individuals with
clinical suspicion of a pleural effusion. Where indicated
complete blood count and abnormal coagulation profile were
repeated on daily basis to monitor deterioration/improvement.
Ultrasound of abdomen was performed in patients with marked
abdominal tenderness. Patients were followed up and their
outcome was noted. 
Calculation of Cost of Care:
Aga Khan University Hospital is one of the largest
private sector health care facility in the metropolitan city of
Karachi. It serves as a tertiary-care referral centre that is
equipped with exceedingly modern heath care facilities and
able to handle the most sick and serious patients. Being a
private hospital, however, the cost of treatment is significantly
higher than that of hospitals in Government sector. .
Information about the approximate cost of care of different
subsets of patients was taken from patient benefit services
department. A rough estimate was calculated by the financial
counselor based on following components: 
1. Approximate length of stay:
This was determined by taking into account the initial
diagnosis and anticipated management plan. 
Estimated Length of Stay (Bed charges X # of days &
daily professional fees X # of days). 
2. Involvement of ICU/SCU:
An average per day charges for SCU is 12k to 18k and
for ICU 20k to 35k. 
3. Major Investigations (if any) (Listed charges).
4. Expensive Pharmacy (if any) (Listed charges).
Statistical Analysis
All variables were entered into Statistical Package for
Social Sciences (SPSS) version 14.0. Means and standard
deviations were calculated for continuous variables and
frequencies for categorical variables. Cross tabulation was
done to determine relationship between different variables and
p-values were calculated as the test of significance. Student's t-
test was used to analyze continuous variables in demographic
and clinical data. The clinical manifestations and laboratory
findings of each group of illness were compared using the chi-
square or Fisher's exact test for proportions and analysis of
variance (1-way ANOVA) for continuous data.
Results
During the study period, from 1st January to 31st
December 2006, 423 patients were admitted with suspected
dengue infection. Of these dengue viral infection was
confirmed in 278 (66%) by positive dengue IgM results. Their
ages ranged from 15 to 72 years with a mean age of 31 ± 12.9
years. The male to female ratio was 1.5:1 with 168 (60%)
males and 110 (40%) females. Average hospital stay was 3.5
days. The frequency of cases varied in different months. Most
of the cases were seen in months of August, September and
October. 267 patients were residents of Karachi. Seven
patients (2.5%) were referred from other parts of the Sindh
province, while three patients were from Punjab. Within the
town, most of the cases were from the east, center and north
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Figure 1: Area-wise Distribution of Dengue Patients.
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of Karachi. 
Two hundred and fifty six (92%) patients were
admitted through the Emergency Room (ER) while the rest 22
(8%) attended the consulting clinics and were hospitalized.
Fever was the most common clinical presentation, found in all
patients on presentation (100%). 
The most frequent haematological abnormality overall
was severe thrombocytopenia (platelet count <50,000/mm3) in
167 (60%) patients. Other abnormalities included Leucopenia
in 124 (45%) patients, elevated transaminases; ALT in 149
(53.5%); AST in 156 (56%) and abnormal renal function
(serum creatinine >1.5 mg/dl) in 68 (24.5%). Deranged PT
(>14 seconds against control of 12 seconds) was seen in 57
(20.5%), deranged aPTT (>35 seconds against control of 30
seconds) in 81 (29%) and hyponatremia (Na+?130mEq/L) in
36 (13%) patients, mainly belonging to DHF and DSS groups.
Twelve (4%) patients had concomitant malarial (vivax and/or
falciparum) infection. These patients received antimalarial
treatment along with symptomatic and supportive therapy for
dengue infection. All had uneventful recovery. Blood cultures
were done in 72% patients. Only 2 patients had positive results
(E. coli and Acinetobacter). They died of septic shock.
Abdominal ultrasound examination was requested in 27
patients; 37% had gall bladder wall thickening consistent with
acalculous cholecystitis.
There were a total of 109/278 (39%) patients with
DHF/DSS. Out of these 82/109 (75%) patients of dengue virus
infection met the criteria for DHF and 27/109 (25%) qualified
for DSS. The male to female ratio was 1.9:1 in DF and 1:1 in
DHF/DSS groups. Age range with the highest percentage of
cases was 21 to 30 years for both DF (31%) and DHF/DSS
(33.9%). Only 9 (8.2 %) cases of DHF/DSS were seen in
patients above 50 years of age. Hospital stay was greater than
3 days in most of the DHF/DSS cases, i.e., 83.5% as compared
to DF, 65.7% cases (p=0.001).
Among 109 DHF/DSS patients mean platelet count
was 67,000 ±59,900. Mean haematocrit was 39.7 ±6.0% and
ranged from 19.2% to 55.5%. PT and aPTT were checked in
66 (60.5%) cases. PT was abnormal in 15 (13.8%) patients.
However, derangement of aPTT was more commonly
observed in DHF/DSS as compared to DF cases (40.3% Vs
33.7%, p=0.044). 
Mean ALT in DHF/DSS was 274 ±646 while highest
level of AST was 10,065 IU/L (Mean 607; SD±1434).
DHF/DSS cases had significantly higher levels of AST
(p=0.017) and ALT (p=0.022) as compared to DF cases (Mean
AST 265, SD±331, Mean ALT 134, SD±164). High ALT (>
100 IU/L) [odds ratio (OR), 1.00; 95% Confidence interval
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Table 2: Descriptive characteristics of patients diagnosed with dengue virus infection.
DF (n=169) % DHF/DSS (n=109) % Overall (n=278) % 'p'-value
Clinical Signs/Symptoms
Facial Flushing 3 (2%) 4 (3%) 7 (2.5%) 0.438
Sore Throat 27 (16%) 14 (13%) 41 (15%) 0.495
Epigastric Pain 85 (50%) 61 (56%) 146 (52.5%) 0.390
Restlessness 1 (1%) 2 (2%) 3 (1%) 0.282
Headache 23 (14%) 13 (12%) 36 (13%) 0.427
Bone/Muscle Pain 53 (31%) 24 (22%) 77 (28%) 0.117
Retroorbital Pain 0 1 (1%) 1 (0.3%) 0.210
Nausea/Vomiting 134 (79%) 83 (76%) 217 (78%) 0.409
Diarrhea 10 (6%) 2 (2%) 12 (4%) 0.05
Chills 129 (76%) 60 (55%) 189 (68%) <0.001
Hepatomegaly 1 (1%) 1 (1%) 2 (0.7%) 1.00
Hypotension 0 26 (24%) 26 (9%) <0.001
Tachycardia 11 (6%) 7 (6%) 19 (7%) 1.00
Tachypnoea 6 (3%) 2 (2%) 8 (3%) 0.487
Skin Rash 55 (32%) 37 (24%) 92 (33%) 0.896
Lymphadenopathy 0 2 (2%) 2 (0.7%) 0.153
Bleeding 6 (3%) 89 (81%) 95 (34%) <0.001
Laboratory Parameters
Raised Haematocrit (> 50) 8 (5%) 26 (24%) 34 (12%) 0.423
Leucopenia (<4) 75 (44%) 49 (45%) 124 (45%) 0.714
Raised Alk. Phosp 7 (4%) 4 (4%) 11 (4%) 1.00
Raised AST (>3times) 57 (34%) 38 (35%) 95 (34%) 0.461
Raised ALT (>3times) 34 (20%) 32 (29%) 66 (24%) 0.207
Raised PT (>14 sec) 37 (22%) 20 (18%) 57 (20.5%) 0.532
Raised aPTT (>35 sec) 43 (25%) 38 (35%) 81 (29%) 0.044
Raised Creatinine (>1.5) 14 (8%) 6 (5.5%) 20 (7%) 0.677
Hyponatremia (<130) 25 (15%) 11 (10%) 36 (13%) 0.221
Thrombocytopenia (<105) 141 (83%) 91 (83%) 232 (83%) 0.636
P-value < 0.05 is considered significant.
(CI), 1.0 to 1.003; p= 0.04] and aPTT (OR 1.03, CI 1.004 to
1.06, p=0.02) were found to be significantly associated with
DHF/DSS cases.
For details of laboratory parameters of the three groups
refer to Table-2.
Five patients died in the DHF/DSS this group. Two had
DHF and three went into shock (DSS). The case fatality rate
was 4.6%. There was no mortality in patients with DF. Out of
five, four patients died of dengue virus infection itself. All four
presented with fever, myalgia and petechiae. 2 of the 4 patients
died of profound shock. One had severe hepatitis (AST 10065
IU/L; ALT 2325 IU/L) and multi-organ failure. Two patients
had concomitant bacterial infection (E.Coli in blood culture)
and died of sepsis. Out of five only one had associated co-
morbidities of diabetes and COPD. 
All patients received symptomatic and supportive
treatment including intravenous fluids, antiemetics and
antipyretics. Blood and blood products, antibiotics and
ionotropic/vasopressor support were administrated as and
when required. Of DF patients, 53/169 (31%) received
prophylactic platelet transfusion when their platelet counts
dropped to ? 20,000; 42/109 (38%) patients in DHF/DSS group
required platelet transfusion. Fresh frozen plasma was infused
in 10 (9.2%) of DHF/DSS patients with DIC and overt
bleeding. Two pregnant females with 22nd and 31st weeks of
gestation had DHF and recovered fully with no apparent
harmful effects on the pregnancy. Two hundred and seventy
three (98%) patients recovered completely with over all
mortality rates of almost 2%. Five patients died two because of
profound shock, one developed acute liver failure and the other
two had concomitant sepsis and co-morbid conditions like
diabetes mellitus and chronic lung disease. 
Cost of Management:
We estimated that the average cost of management of a
patient with DF varied from 20,000 to 40,000 PKR. In case, the
patients requiring critical care stay (DHF/DSS cases); the cost
was as high as 150,000 to 200,000 PKR for 3-4 days. 
Discussion 
In Karachi, DF has been recognized as one of the
causes of fever since 1994 when the Ist major outbreak of DHF
occurred over here. Very few cases were seen until September
2005. Thereafter up to December major hospitals of the city
reported a rapid increase in the number of cases of probable
dengue infection. Very few were laboratory confirmed cases.
2006 outbreak is considered to be the largest epidemic of
dengue in Karachi. Our study reports the clinical profile of the
IgM confirmed cases. DHF is considered to be a disease of
paediatric population and now a leading cause of
hospitalization and death among children.9 In our study, 80%
of patients with DHF/DSS were below 40years (mean 26 ±
7.5years). This observation is consistent with reports from
other endemic countries. Gupta et al10 from India showed a
maximum number of cases between the ages of 21 and 30
years. Likewise in Singapore 2005 outbreak, young adults
were predominantly affected by DHF.11 Peak incidence is
noted in August, September and October (Figure 2). The reason
for this is not entirely clear. One explanation can be the heavy
rains of monsoon season, which usually start in July and
August, resulting in stagnant water that serves as breeding
ground for vectors of this virus. Hot summer seasonal peak is
also reported in studies from India and Bangladesh.10,12
Presenting symptoms of fever, nausea/vomiting,
epigastric pain, bleeding tendencies and laboratory features of
thrombocytopenia, elevated liver enzymes, deranged PT/aPTT
were not different from other studies.13,14 Hepatic dysfunction
and bleeding from the gastrointestinal tract secondary to
associated coagulopathy are manifestations of severe dengue
infection.15 Most of our DHF/DSS patients had abnormal
levels of AST and ALT as compared to DF. Liver injury from
dengue virus is mediated by its direct infection of hepatocytes
and Kupffer cells.16 Marked hepatic dysfunction has been
documented in severe cases.17 Disseminated intravascular
coagulation, which occurs in DHF/DSS patients and consumes
both platelets and clotting factors, may contribute to the
prolongation of aPTT. Therefore, elevated aPTT and
prolongation more than twice the control may serve as a
marker for dengue shock syndrome. 
The over all CFR in the Southeast Asia region is now
less than 1%.18 However, rates vary significantly between
countries and hospitals. In this study mortality was 4.6% in
patients belonging to the DHF/DSS group, which is
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Figure 2: Monthly distribution of Dengue cases.
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comparable with other regional studies.13,19 It means that early
diagnosis, appropriate investigations, strict monitoring, and
prompt management could help in reducing mortality in
dengue haemorrhagic fever. Increase in dengue mortality is
considered to be a reflection of the increase in the proportion of
DF patients who develop DHF/DSS. Dengue serotype 3
generally causes more severe infection. Serum samples from
suspected DHF/DSS cases in a small epidemic of 2005
revealed DENV-3 as the cause of the DHF.20 High mortality in
our patients may be a reflection of re-infection, infection with
a virulent viral serotype, late presentation to the hospital and
lack of uniformity in patient management because of relatively
recent introduction of dengue in our population.
Frequency of DF outbreaks is likely to increase in
Pakistan in conjunction with increasing numbers of cases of
severe disease and high indices of the principal mosquito
vector Aedes aegypti. Epidemics of DHF/DSS may therefore
become an increasingly important public health problem in
Pakistan. One important aspect of any illness is cost of
treatment. Being an economically underprivileged country
where the individual patients have to bear the cost of health
care, the financial implications of the disease management are
worth taking into consideration. In addition to vector control,
key health sector response for reduction of mortality and
morbidity lies primarily in two areas: early detection of cases
and improved & cost effective management of patients.
Mortality in excess of 1% may be considered the consequence
of inadequate care, late diagnosis and delayed hospitalization.
A hospital-based study during the dengue outbreak in Delhi
revealed that mortality could be very low in patients who came
early to the hospital.21 Late presentation was also strongly
associated with increased mortality in children with DHF in the
Philippines.22
The study confirms the epidemic of DF in this region.
Karachi is the largest city of the province with more than 15
million people; most of who are living in poorly built houses
with lack of water and solid waste disposal. Effective disease
prevention programme should include vector control by
chemical, biological or environmental measures, mass
education programmes of the community to seek early medical
care and strengthen the knowledge of family
physicians/general practitioners to recognize the warning signs
of the disease.
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